Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Sat Jun 16 00:00:00 GMT-04:00 2018
Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Su ...
PDF (246 KB)
Wed Jun 06 00:00:00 GMT-04:00 2018
Daiichi Sankyo’s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 ...
PDF (166 KB)
Wed Jun 06 00:00:00 GMT-04:00 2018
Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with ...
PDF (190 KB)
Mon Jun 04 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Signific ...
PDF (132 KB)
Fri Jun 01 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients wi ...
PDF (203 KB)
Fri Jun 01 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Preliminary Phase 1 Data for Antibody Drug Conjugate U3-1402 in Patients wi ...
PDF (271 KB)
Thu May 31 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or ...
PDF (189 KB)
Wed May 16 00:00:00 GMT-04:00 2018
Daiichi Sankyo to Present New Data on Multiple Compounds Including Antibody Drug Conjugates DS-8201 ...
PDF (295 KB)
Mon May 14 00:00:00 GMT-04:00 2018
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
PDF (171 KB)
Tue May 08 00:00:00 GMT-04:00 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared ...
PDF (268 KB)
Showing 1 - 10 of 45 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...